These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 8674896)

  • 1. Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors.
    Vlassara H; Bucala R
    Diabetes; 1996 Jul; 45 Suppl 3():S65-6. PubMed ID: 8674896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus.
    Hori O; Yan SD; Ogawa S; Kuwabara K; Matsumoto M; Stern D; Schmidt AM
    Nephrol Dial Transplant; 1996; 11 Suppl 5():13-6. PubMed ID: 9044300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications.
    Wautier JL; Wautier MP; Schmidt AM; Anderson GM; Hori O; Zoukourian C; Capron L; Chappey O; Yan SD; Brett J
    Proc Natl Acad Sci U S A; 1994 Aug; 91(16):7742-6. PubMed ID: 8052654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of receptors for advanced glycation end-products in occlusive vascular and renal disease.
    Bierhaus A; Ritz E; Nawroth PP
    Nephrol Dial Transplant; 1996; 11 Suppl 5():87-90. PubMed ID: 9044315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent progress in advanced glycation end products and diabetic complications.
    Vlassara H
    Diabetes; 1997 Sep; 46 Suppl 2():S19-25. PubMed ID: 9285494
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular mechanisms of diabetic angiopathy--clues for innovative therapeutic interventions.
    Bierhaus A; Ziegler R; Nawroth PP
    Horm Res; 1998; 50 Suppl 1():1-5. PubMed ID: 9676989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Participation of toxic AGEs (TAGE) in a variety of diseases].
    Takeuchi M
    Nihon Yakurigaku Zasshi; 2012 May; 139(5):193-7. PubMed ID: 22687870
    [No Abstract]   [Full Text] [Related]  

  • 8. [AGE receptor].
    Matsumoto K; Sano H; Horiuchi S
    Nihon Rinsho; 1997 Nov; 55 Suppl():867-71. PubMed ID: 9434579
    [No Abstract]   [Full Text] [Related]  

  • 9. Advanced glycosylation end products in diabetic renal and vascular disease.
    Bucala R; Vlassara H
    Am J Kidney Dis; 1995 Dec; 26(6):875-88. PubMed ID: 7503061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure.
    Ahmad S; Siddiqui Z; Rehman S; Khan MY; Khan H; Khanum S; Alouffi S; Saeed M
    Curr Vasc Pharmacol; 2017; 15(4):352-364. PubMed ID: 28356033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAGE: a novel target for drug intervention in diabetic vascular disease.
    Hudson BI; Schmidt AM
    Pharm Res; 2004 Jul; 21(7):1079-86. PubMed ID: 15290845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAGE: a novel cellular receptor for advanced glycation end products.
    Schmidt AM; Hori O; Cao R; Yan SD; Brett J; Wautier JL; Ogawa S; Kuwabara K; Matsumoto M; Stern D
    Diabetes; 1996 Jul; 45 Suppl 3():S77-80. PubMed ID: 8674899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new dark side of the Maillard's products.
    Wautier JL
    Diabetes Metab; 2003 Feb; 29(1):86-7. PubMed ID: 12629454
    [No Abstract]   [Full Text] [Related]  

  • 14. Regulation of RAGE for attenuating progression of diabetic vascular complications.
    Win MT; Yamamoto Y; Munesue S; Saito H; Han D; Motoyoshi S; Kamal T; Ohara T; Watanabe T; Yamamoto H
    Exp Diabetes Res; 2012; 2012():894605. PubMed ID: 22110482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus.
    Lee J; Yun JS; Ko SH
    Nutrients; 2022 Jul; 14(15):. PubMed ID: 35956261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced glycation end products: sparking the development of diabetic vascular injury.
    Goldin A; Beckman JA; Schmidt AM; Creager MA
    Circulation; 2006 Aug; 114(6):597-605. PubMed ID: 16894049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of advanced glycation endproducts (AGE) and receptor for AGE on vascular smooth muscle cell growth.
    Wang R; Kudo M; Yokoyama M; Asano G
    J Nippon Med Sch; 2001 Dec; 68(6):472-81. PubMed ID: 11744927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Possible participation of advanced glycation endproducts and their receptor system in the development of diabetic vascular complications].
    Yamamoto Y; Sakurai S; Watanabe T; Yonekura H; Yamamoto H
    Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):49-55. PubMed ID: 12617038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
    Yamagishi S
    Exp Gerontol; 2011 Apr; 46(4):217-24. PubMed ID: 21111800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced glycation end products, their receptors and diabetic angiopathy.
    Wautier JL; Guillausseau PJ
    Diabetes Metab; 2001 Nov; 27(5 Pt 1):535-42. PubMed ID: 11694852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.